Clinical and Economic Evaluation of the Blood Purification with Selective Sorption Techniques in ICU Patients

Abstract

The objective was to analyze the clinical and economic feasibility of using selective methods of lipopolysaccharide (LPS) sorption for sepsis treatment.Materials and methods. A clinical and economic model was used to assess the feasibility of using some technologies of selective lipopolysaccharide sorption. The model was developed in accordance with the current industry standard «Clinical and Economic Research» used in Russia. The target population was patients of 18 years old and older with sepsis. The methodology involved the evaluation of available randomized clinical trials, as well as studies involving data from network meta-analyses and systematic reviews of the use of the studied technologies. The calculation of direct medical and indirect non-medical costs was made with an analysis of the impact on the budget during the first year and on the time horizon for five years.Results. The value of direct and indirect costs was determined when using sorption devices based on Efferon LPS, Toraymyxin, Alteco LPS Adsorber, Toxipak columns. It was shown that among the therapeutic alternatives, the use of the Efferon LPS column had the least burden on the budget.Conclusion. The use of selective lipopolysaccharide sorption technologies in the intensive care program for sepsis patients, although accompanied by an increase in direct and indirect financial costs, leads to budget savings in the medium term. Improving the mechanism for compensating the costs of using this technology is a promising way to improve the outcomes of sepsis treatment.